Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

NCT06393751 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

NIH

Sponsor class

Stopped Other - Protocol moved to Withdrawn

Conditions

Platinum-Refractory Fallopian Tube Carcinoma
Platinum-Refractory Ovarian Carcinoma
Platinum-Refractory Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Adenocarcinoma
Recurrent Fallopian Tube Carcinosarcoma
Recurrent Fallopian Tube Clear Cell Adenocarcinoma
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
Recurrent Fallopian Tube Undifferentiated Carcinoma
Recurrent High Grade Endometrioid Adenocarcinoma
Recurrent Ovarian Adenocarcinoma
Recurrent Ovarian Carcinosarcoma
Recurrent Ovarian Clear Cell Adenocarcinoma
Recurrent Ovarian High Grade Serous Adenocarcinoma
Recurrent Ovarian Seromucinous Carcinoma
Recurrent Ovarian Undifferentiated Carcinoma
Recurrent Platinum-Resistant Fallopian Tube Carcinoma
Recurrent Platinum-Resistant Ovarian Carcinoma
Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Primary Peritoneal Adenocarcinoma
Recurrent Primary Peritoneal Carcinosarcoma
Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Recurrent Primary Peritoneal Undifferentiated Carcinoma

Interventions

BIOLOGICAL: Bevacizumab
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
DRUG: Paclitaxel
DRUG: Tolinapant

Sponsor

National Cancer Institute (NCI)